Global Hemoglobinopathies Market size is expected to reach nearly US$ 20011.1 Mn by 2029 with the CAGR of 10.3% during the forecast period. The global Hemoglobinopathies market report is a comprehensive analysis of the industry, market, and key players. The report has covered the market by demand and supply-side by segments. The global Hemoglobinopathies market report also provides trends by market segments, technology, and investment with a competitive landscape.To know about the Research Methodology :- Request Free Sample Report
Global Hemoglobinopathies Market Overview
Hemoglobinopathies are blood disorders that affect red blood cells. These diseases can be genetic which results in an abnormal structure of one of the hemoglobin molecule's globin chains. These are inherited as single-gene diseases, resulting in illnesses such as sickle cell disease. Pre-implantation genetic diagnosis, genetic and blood testing, alkaline and acid gel electrophoresis, hemoglobin electrophoresis, prenatal genetic testing, and HbA2 quantitative analysis by ion-exchange column chromatography have been the most frequently used tests for diagnosing hemoglobinopathies and thalassemia disorders. According to the most recent Reports and Data analysis, the global Hemoglobinopathies market was valued at US$ 5 bn in 2018 and is anticipated to grow at a rate of CAGR xx% reaching 14 Bn during the forecast period. It is regarded as the most common inherited disease on the planet. Furthermore, as a result of immigration, hemoglobinopathies have become much more common in central and northern Europe, including Germany.Global Hemoglobinopathies Market Dynamics
The rising incidence of hemoglobinopathies globally, high-level diseases, a variety of government support initiatives, and NGO funding is driving the hemoglobinopathies market. Factors such as innovative diagnostic methods, favorable screening techniques and financial methodologies like genetic testing, and the development of rapid point-of-care diagnostic methods. Inadequate healthcare facilities and decreased levels of diagnosis of diseases, as well as the rising numbers of hemoglobinopathies like Sickle Cell Disease, thalassemia, HbC, and Hb E, are expected to be major growth drivers for the market. The increasing incidences of hemoglobinopathies in various economies, higher infection occurrence in developing countries, various government initiatives, and non-government institution financial support are driving the hemoglobinopathies market. A few of the medications to treat hemoglobinopathies include NiCord, ZFP Transcription Factors, ALN-TMP, and Drug Targeting PRMT5. However, a lack of cure will restrain the market from growing. Failure of developing treatment and clinical trials of sickle cell anemia is expected to obstruct market growth. Pfizer announced that the Rivipansel pivotal study, which was intended to assess the efficacy and safety of rivipansel in participants aged six and older with sickle cell disease, had failed to fulfill its main objectives and desired results.Global Hemoglobinopathies Market Segment Analysis
By Type, The segment of sickle cell anemia dominate most percent of the market in 2020 and is anticipated to witness the fastest growth during the forecast timeframe. Due to growing initiatives by biopharmaceutical companies and non-profit organizations aimed at increasing access to SCD treatment. Moreover, sickle cell anemia affects an estimated 3 lacks of babies annually. As per the reports, an estimated 40% of citizens in African nations are carriers of the sickle cell trait. The increasing global burden of the health care field will propel the market growth during the forecast period The segment of thalassemia is anticipated to register significant growth in the forecast period. Due to eco-friendly, rapid, and technologically advanced methods of test and diagnostic. Presence of key players which provide a molecular diagnostic test which is based on PCR polymerase Chain Reaction and Multiplex Ligation Dependent Probe Amplification for detection of thalassemia. Which are expected to grow the market in the coming years. By therapy type, Blood Transfusion has shown growth in recent years. it is the primary step in the treatment of hemoglobin diseases because the frequency of blood transfusion is higher as compared to the other thalassemia diseases. Every 3 – 4 weeks it is needed to be performed to maintain the normal level of blood components. Moreover conducting frequent blood transfusions can increase the % of getting infected by the disease and high blood iron levels. The overall blood chelation and blood transfusion were on the decline due to the pandemic in 2020. The segment of Bone Marrow Transplant is expected to grow significantly during the forecast period. BMT is conducted when all other therapies like blood transfusion fail and are effective at the early stages of the disease. It provides patients with adequate bone marrow who are not able to produce a required number of cells in the body to replace damaged ones. And is in increasing use to serve thalassemia and sickle cell disease.Global Hemoglobinopathies Market Regional Insights:
Asia-Pacific is expected to have a high CAGR during the forecast period. Rising government Initiatives and investment for infrastructural development combined with enhanced facilities for research and development by major countries & the presence of patients suffering from thalassemia and sickle cell disease Are expected to boost the market growth. India, China, and South Korea are the major contributors in the region. The availability of an adequate healthcare system and professionals will grow the market further. India being a global leader in the medical field is trying to develop new diagnostic and screening methods that will help in the treatment of disease at a primitive stage. North America currently dominates the hemoglobinopathies market and will do so for the foreseeable future. This is due to the presence of significant key players. Today, North America is a global financial superpower, with nearly 500 million people are living in three democratic countries, and holds the largest market share by revenue by 40%. USA, Canada, and Mexico contribute to a majority of global GDP as an Increase in the investment for infrastructural as well as Research development is anticipated to boost the market growth in the region. Joint ventures and medical drug and infrastructural agreements between firms plus awareness programs by government and various research & health organizations are anticipated to boost the market in the region in coming years. Increased migration of people from other regions to Europe and sectors of North America plus improved treatment and diagnosis for genetic diseases like thalassemia and sickle cell is likely to grow the market in the region. As compared to other regions, migration is high in the regions of North America and Europe. The objective of the report is to present a comprehensive analysis of the Global Hemoglobinopathies market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Global Hemoglobinopathies Market dynamics, structure by analyzing the market segments and project the Global Hemoglobinopathies Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Hemoglobinopathies Market make the report investor’s guide.Global Hemoglobinopathies Market Scope: Inquire before buying
Global Hemoglobinopathies Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 10074.9 Mn. Forecast Period 2023 to 2029 CAGR: 10.3% Market Size in 2029: US $ 20011.1 Mn. Segments Covered: by Type Thalassemia Alpha Thalassemia Beta Thalassemia Sickle Cell Disease Other HB Variants Diseases by Therapy Type Blood transfusion Iron chelation therapy Bone marrow transplant Others by Test Type Red blood cell (RBC) count test Genetic testing Liquid chromatography (HPLC) test Hemoglobin isoelectric (Hb IEF) focusing Hemoglobin electrophoresis (Hb ELP) test Hemoglobin solubility test Global Hemoglobinopathies Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe) Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina, Columbia and Rest of South America)Global Hemoglobinopathies Market, Key Players are
1. Global Blood Therapeutics 2. Neusoft Medical Systems Co., Ltd 3. Bluebird Bio, Inc. 4. Emmaus Life Sciences Inc. 5. Prolong Pharmaceuticals 6. Celgene Corporation 7. Alnylam Pharmaceuticals 8. Gamida Cell 9. Acceleron Pharma 10. Mast Therapeutic 11. HemaQuest Pharmaceuticals 12. Sanofi 13. Sangamo Therapeutics, Inc. 14. Pifzer, 15. Bioverative inc Frequently Asked Questions: 1. Which region has the largest share in Global Hemoglobinopathies Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Hemoglobinopathies Market? Ans: The Global Hemoglobinopathies Market is growing at a CAGR of 10.3% during forecasting period 2023-2029. 3. What is scope of the Global Hemoglobinopathies Market report? Ans: Global Hemoglobinopathies Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Hemoglobinopathies Market? Ans: The important key players in the Global Hemoglobinopathies Market are – Global Blood Therapeutics, Neusoft Medical Systems Co., Ltd, Bluebird Bio, Inc., Emmaus Life Sciences Inc., Prolong Pharmaceuticals, Celgene Corporation, Alnylam Pharmaceuticals, Gamida Cell, Acceleron Pharma, Mast Therapeutic, HemaQuest Pharmaceuticals, Sanofi, Sangamo Therapeutics, Inc., Pifzer,, Bioverative inc. 5. What is the study period of this Market? Ans: The Global Hemoglobinopathies Market is studied from 2022 to 2029.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Hemoglobinopathies Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2019 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Hemoglobinopathies Products Market 3.4. Geographical Snapshot of the Hemoglobinopathies Products Market, By Manufacturer share 4. Global Hemoglobinopathies Market Overview, 2022-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Hemoglobinopathies Market 5. Supply Side and Demand Side Indicators 6. Global Hemoglobinopathies Market Analysis and Forecast, 2022-2029 6.1 Hemoglobinopathies Market Size & Y-o-Y Growth Analysis 7. Global Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 7.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 7.1.1. Thalassemia 7.1.1.1. Alpha Thalassemia 7.1.1.2. Beta Thalassemia 7.1.2. Sickle Cell Disease 7.1.3. Other HB Variants Diseases 7.2. Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 7.2.1. Blood transfusion 7.2.2. Iron chelation therapy 7.2.3. Bone marrow transplant 7.2.4. Others 7.3. Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 7.3.1. Red blood cell (RBC) count test 7.3.2. Genetic testing 7.3.3. Liquid chromatography (HPLC) test 7.3.4. Hemoglobin isoelectric (Hb IEF) focusing 7.3.5. Hemoglobin electrophoresis (Hb ELP) test 7.3.6. Hemoglobin solubility test 7.4. Market Size (Value) Estimates & Forecast By Region, 2022-2029 7.4.1. North America 7.4.2. Europe 7.4.3. Asia-Pacific 7.4.4. Middle East & Africa 7.4.5. South America 8. North America Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 8.1. Market Size (Value) Estimates & Forecast By Type, 2022-2029 8.1.1 Thalassemia 8.1.1.1 Alpha Thalassemia 8.1.1.2 Beta Thalassemia 8.1.2 Sickle Cell Disease 8.1.3 Other HB Variants Diseases 8.2. Market Size (Value) Estimates & Forecast By Therapy Type, 2019-202 8.2.1 Blood transfusion 8.2.2 Iron chelation therapy 8.2.3 Bone marrow transplant 8.2.4 Others 8.3. Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 8.3.1. Red blood cell (RBC) count testGenetic testing 8.3.2. Liquid chromatography (HPLC) test 8.3.3. Hemoglobin isoelectric (Hb IEF) focusing 8.3.4. Hemoglobin electrophoresis (Hb ELP) test 8.3.5. Hemoglobin solubility test 8 North America Hemoglobinopathies Market Analysis and Forecasts, By Country 8.2 Market Size (Value) Estimates & Forecast By Country, 2022-2029 8.2.1 US 8.2.2 Canada 8.2.3 Mexico 9 U.S. Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 9.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 9.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 9.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 10 Canada Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 10.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 10.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 10.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 11 Mexico Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 11.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 11.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 11.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 12 Europe Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 12.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 12.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 12.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 13 Europe Hemoglobinopathies Market Analysis and Forecasts, By Country 13.2 Market Size (Value) Estimates & Forecast By Country, 2022-2029 13.2.1 U.K 13.2.2 France 13.2.3 Germany 13.2.4 Italy 13.2.5 Spain 13.2.6 Sweden 13.2.7 CIS Countries 13.2.8 Rest of Europe 14 U.K. Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 14.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 14.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 14.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 15 France Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 15.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 15.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 15.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 16 Germany Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 16.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 16.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 16.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 17 Italy Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 17.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 17.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 17.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 18 Spain Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 18.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 18.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 18.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 19 Sweden Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 19.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 19.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 19.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 20 CIS Countries Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 20.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 20.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 20.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 21 Rest of Europe Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 21.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 21.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 21.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 22 Asia Pacific Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 22.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 22.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 22.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 23 Asia Pacific Hemoglobinopathies Market Analysis and Forecasts, by Country 23.2 Market Size (Value) Estimates & Forecast By Country, 2022-2029 23.2.1 China 23.2.2 India 23.2.3 Japan 23.2.4 South Korea 23.2.5 Australia 23.2.6 ASEAN 23.2.7 Rest of Asia Pacific 24 China Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 24.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 24.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 24.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 25 India Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 25.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 25.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 25.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 26 Japan Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 26.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 26.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 26.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 27 South Korea Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 27.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 27.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 27.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 28 Australia Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 28.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 28.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 28.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 28.5 Market Size (Value) Estimates & Forecast By Region, 2022-2029 29 ASEAN Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 29.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 29.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 29.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 30 Rest of Asia Pacific Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 30.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 30.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 30.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 31 Middle East Africa Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 31.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 31.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 31.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 32 Middle East Africa Hemoglobinopathies Market Analysis and Forecasts, by Country 32.2 Market Size (Value) Estimates & Forecast by Country, 2022-2029 32.2.1 South Africa 32.2.2 GCC Countries 32.2.3 Egypt 32.2.4 Nigeria 32.2.5 Rest of ME&A 33 South Africa Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 33.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 33.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 33.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 34 GCC Countries Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 34.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 34.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 34.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 35 Egypt Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 35.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 35.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 35.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 36 Nigeria Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 36.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 36.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 36.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 37 Rest of ME&A Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 37.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 37.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 37.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 38 South America Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 38.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 38.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 38.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 39 South America Hemoglobinopathies Market Analysis and Forecasts, by Country 39.2 Market Size (Value) Estimates & Forecast by Country, 2022-2029 39.2.1 Brazil 39.2.2 Argentina 39.2.3 Rest of South America 40 Brazil Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 40.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 40.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 40.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 41 Argentina Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 41.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 41.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 41.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 42 Rest of South America Hemoglobinopathies Market Analysis and Forecasts, 2022-2029 42.2 Market Size (Value) Estimates & Forecast By Type, 2022-2029 42.3 Market Size (Value) Estimates & Forecast By Therapy Type, 2022-2029 42.4 Market Size (Value) Estimates & Forecast By Test Type, 2022-2029 43 Competitive Landscape 43.2 Geographic Footprint of Major Players in the Global Hemoglobinopathies Market 43.3 Competition Matrix 43.3.1 Competitive Benchmarking of Key Players By Price, Presence, Market Share, Test Types and R&D Investment 43.3.2 New Product Launches and Product Enhancements 43.3.3 Market Consolidation 43.3.3.1 M&A by Regions, Investment and Verticals 43.3.3.2 M&A, Forward Integration and Backward Integration 43.3.3.3 Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 43.4 Company Profile : Key Players 43.4.1 Global Blood Therapeutics 43.4.1.1 Company Overview 43.4.1.2 Financial Overview 43.4.1.3 Geographic Footprint 43.4.1.4 Product Portfolio 43.4.1.5 Business Strategy 43.4.1.6 Recent Developments 45.3.2 Neusoft Medical Systems Co., Ltd 45.3.3 Bluebird Bio, Inc. 45.3.4 Emmaus Life Sciences Inc. 45.3.5 Prolong Pharmaceuticals 45.3.6 Celgene Corporation 45.3.7 Alnylam Pharmaceuticals 45.3.8 Gamida Cell 45.3.9 Acceleron Pharma 45.3.10 Mast Therapeutic 45.3.11 HemaQuest Pharmaceuticals 45.3.12 Sanofi 45.3.13 Sangamo Therapeutics Inc. 45.3.14 Pifzer, 45.3.15 Bioverative inc. 46 Primary Key Insights